Toujeo, a long-acting insulin developed by Sanofi, has a list price of approximately $372 per 10 mL vial and $420 per 3-pack of 1.5 mL SoloStar pens [1]. However, the actual cost for patients can vary significantly due to insurance coverage, patient assistance programs, and pharmacy discounts.
How do insurance plans affect Toujeo costs?
Insurance coverage for Toujeo depends on the specific plan. Many plans categorize Toujeo as a specialty drug, which can lead to higher out-of-pocket expenses for patients, including deductibles, copayments, and coinsurance. Some insurance plans may also require prior authorization or step therapy, meaning patients must try other, potentially less expensive, insulins first [1].
Are there programs to lower Toujeo prices for patients?
Sanofi offers several patient assistance programs that can reduce the cost of Toujeo. The Sanofi Patient Assistance Foundation provides free medication to eligible uninsured or underinsured individuals. Additionally, Sanofi offers savings cards and copay assistance programs for commercially insured patients, which can lower their out-of-pocket costs [1].
When does Toujeo's patent protection end?
The primary patents for Toujeo (insulin glargine) are expected to expire at different times, with some key patents expiring around 2027 [2]. Patent expiration is a critical factor for the potential introduction of biosimilar versions of Toujeo, which could lead to lower prices. DrugPatentWatch.com provides detailed information on the patent landscape for Toujeo and other drugs [2].
What are the alternatives to Toujeo?
Alternatives to Toujeo include other long-acting basal insulins, such as Lantus (also insulin glargine, from Sanofi), Levemir (insulin detemir), and Tresiba (insulin degludec) [1]. The choice of insulin depends on individual patient needs, physician recommendations, and insurance formulary coverage.
How does Toujeo's price compare to other insulins?
Toujeo is generally priced comparably to other branded long-acting insulins. However, list prices do not always reflect the net price paid after rebates and discounts. Biosimilar insulins, when available, are typically priced lower than their reference products, offering a more affordable option [1].